Immune-Oncology Biomarkers of Response & Resistance
Why do some patients respond to checkpoint inhibitor therapy while others develop resistance? An example analysis across four melanoma immunotherapy trials.
All analyses shown are exploratory and intended to support biomarker hypothesis generation rather than clinical validation.
This example analysis looks at data from four melanoma immunotherapy clinical trials, covering 256 patients treated with anti-PD-L1 or anti-CTLA-4 therapies.
By integrating RNA sequencing and whole exome sequencing data, the analysis identifies candidate biomarkers associated with treatment response and resistance, building a fuller picture of tumour immune activity across the trial cohorts.
Identified features are prioritised for downstream biological review and independent validation.
Powered by Sonrai Discovery
The analysis was performed using Sonrai Discovery, Sonrai's governed environment for reproducible multi-modal data analysis.
See where this kind of biomarker analysis leads
Explore how response and resistance biomarkers like these feed into biomarker-guided patient stratification.
Explore biomarker-driven patient stratification